Equity Details
Price & Market Data
Price: $0.0554
Daily Change: -$0.0068 / 12.27%
Daily Range: $0.053 - $0.0622
Market Cap: $5,042,456
Daily Volume: 280,430
Performance Metrics
1 Week: -4.77%
1 Month: 32.26%
3 Months: -10.45%
6 Months: -36.52%
1 Year: -65.35%
YTD: -25.41%
About PharmaTher Holdings Ltd. (PHRRF)
Access real-time market insights for PharmaTher Holdings Ltd. (PHRRF). The stock is trading at 0.0554, reflecting a daily change of -$0.0068 / 12.27%. With a market capitalization of 5,042,456, it showcases performance metrics including 6-month (-36.52%) and 1-month (32.26%) returns.
Details
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia, procedural sedation as well as depression, surgical and pain management. It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX wearable pump for the maintenance of general anesthesia for diagnostic, surgical procedures and pain indications. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS; with the University of Arizona for the development and commercialization of ketamine in the treatment of Parkinson's disease; as well as holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology. The company was incorporated in 2019 and is headquartered in Toronto, Canada.